Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20260270 | 0.93 | SMPD1 (0.43) | TSHRFDPSSMPD1TRPM8 | |
| SCHEMBL29198794 | 0.81 | TSHR (0.43) | TSHRCYP3A4L3MBTL1FDPSSMPD1 | |
| SCHEMBL10880316 | 0.81 | TSHR (0.46) | TSHRCYP3A4L3MBTL1FDPSSMPD1 | |
| SCHEMBL29068466 | 0.77 | SMPD1 (0.53) | FDPSSMPD1 | |
| SCHEMBL3823536 | 0.77 | TSHR (0.46) | TSHRCYP3A4L3MBTL1FDPSSMPD1 | |
| SCHEMBL6895576 | 0.76 | TSHR (0.55) | TSHRCYP3A4 | |
| SCHEMBL212641 | 0.76 | TSHR (0.44) | TSHRCYP3A4L3MBTL1FDPSSMPD1 | |
| SCHEMBL17467185 | 0.75 | CYP3A4 (0.48) | TSHRCYP3A4TRPM8 | |
| SCHEMBL18924782 | 0.74 | SMPD1 (0.46) | TSHRFDPSSMPD1TRPM8 | |
| SCHEMBL6893713 | 0.74 | CYP3A4 (0.47) | TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | TSHR 1280/4885CYP3A4 257/4885L3MBTL1 3121/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | TSHR 1280/4885CYP3A4 257/4885L3MBTL1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.